Clinical trials: Hepatic Chemotherapy
Unresectable Hepatocellular Carcinoma
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
The efficacy and safety of HAIC combined with tyrosine kinase inhibitor and immunotherapy have been proved by the clinical research.
- Trial name
- NCT05135364
- Testing
- Camrelizumab, HAIC, TKI
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Yue Han
Hepatocellular Carcinoma
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of Cadonilimab(AK104) in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment…
- Trial name
- NCT06406634
- Testing
- Cadonilimab, Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hunan Cancer Hospital
Hepatocellular Carcinoma
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin and raltitrexed plus lenvatinib and camrelizumab in patients with unresectable hepatocellular carcinoma…
- Trial name
- NCT05003700
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Camrelizumab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatocellular Carcinoma, Chemotherapy Effect
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
The goal of this clinical trial is to compare HAIC concurrently with sequentially combined with targeted and immunotherapies in terms of efficacy and safety in patients with potentially resectable intermediate and advanced HCC…
- Conditions
- Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
- Trial name
- HAIC (NCT06041477)
- Testing
- Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU, Concurrent Lenvatinib, Concurrent PD-1 antibody
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Neoplasm Metastasis
Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
The purpose of this study is to determine whether capecitabine is effective to prevent disease recurrence after curative hepatic resection in patients with hepatocellular carcinoma.
- Trial name
- NCT00561522
- Testing
- Capecitabine, No other preventive treatment
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Fudan University
Cholangiocarcinoma, Intrahepatic
Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma
Oncolytic viruses can selectively replicate in and destroy tumor cells. Recent studies indicate that recombinant human adenovirus type 5 (H101), which is the first approved oncolytic virus drug in the world, shows anti-tumor…
- Trial name
- NCT05124002
- Testing
- Recombinant Human Adenovirus Type 5, HAIC of FOLFOX
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
HCC, Transarterial Chemoembolization
cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
explore the effectiveness and safety of conventional transarterial chemoembolization (cTACE) or transarterial chemoembolization (DEB-TACE) plus hepatic arterial Infusion chemotherapy (HAIC) combined with regorafenib and anti-PD-1…
- Conditions
- HCC, Transarterial Chemoembolization, Hepatic Arterial Infusion Chemotherapy, Regorafenib
- Trial name
- NCT05025592
- Testing
- Regorafenib, cTACE/DEB-TACE-HAIC
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
Phase II trial to study the effectiveness of hepatic arterial infusion plus chemotherapy in treating patients who have colorectal cancer metastatic to the liver.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastases, Recurrent Colon Cancer
- Trial name
- NCT00026234
- Testing
- floxuridine, dexamethasone, oxaliplatin
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC
Zoledronic acid was initially used for bone metastases in various malignancies. However, it is unknown whether hepatic arterial infusion chemotherapy combined with zoledronic acid can improve overall survival of unresectable…
- Trial name
- NCT05866172
- Testing
- HAIC, Zoledronic acid
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of oxaliplatin alone in patients with hepatocellular…
- Trial name
- NCT03468231
- Testing
- Sorafenib, HAIC of FOLFOX, HAIC of OXA
- Where
- 7 sites in China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
Atezolizumab and bevacizumab was approve for advanced unresectable hepatocellular carcinoma (aHCC). Whether the additional of transartial chemobolization and hepatic artery infusion chemotherapy will improve the response rate for…
- Trial name
- NCT05751343
- Testing
- TACE-HACI, plus atezolizumab-bevacizumab
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma
Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.
This study is a single-center, open-label Phase II clinical trial, aiming to enroll approximately 30 unresectable BCLC stage B or C hepatocellular carcinoma (HCC) patients from China.
- Trial name
- NCT06375486
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Breast Cancer, Liver Metastases
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer
This is a phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tumour in combination with trastuzumab (Herceptin®)…
- Trial name
- NCT01387373
- Testing
- oxaliplatin, capecitabine, trastuzumab
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- Dorte Nielsen
HepatoCellular Carcinoma, Portal Vein Thrombosis
Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis
According to the Barcelona clinic liver cancer (BCLC) staging treatment guideline, sorafenib is recommended for Hepatocellular Carcinoma (HCC) with Portal Vein Tumor Thrombosis (PVTT), but HCC with major PVTT (in the main trunk…
- Trial name
- NCT03009461
- Testing
- HAIC, Sorafenib
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Peking University
Liver Metastasis Colon Cancer, ctDNA Genotype
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment
Hepatic arterial infuison chemothearpy (HAIC), targeted therapy, and programmed death-1 (PD-1) inhibitors have been demonstrated to be effective for colorectal cancer liver metastasis (CRCLM).
- Conditions
- Liver Metastasis Colon Cancer, ctDNA Genotype, MSS, Failed From Standard Treatment
- Trial name
- NCT06199232
- Testing
- HAIC+targeted therapy+PD-1 inhibitor
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Peking University
Liver Cancer (Primary and Metastatic)
A Study of Combination Therapy in Patients With Resectable Liver Cancer
This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of an initial combination treatment strategy followed by surgery in patients with cancer.
- Trial name
- Archer (NCT07684040)
- Testing
- Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Plus Rivoceranib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Germ Cell Tumors, Hepatic Cancer
Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
Life-threatening thrombocytopenia (low platelet count) and neutropenia (low white blood count) remain the major dose-limiting toxicities following chemotherapy treatment for cancer.
- Conditions
- Germ Cell Tumors, Hepatic Cancer, Neuroblastoma, Osteosarcoma
- Trial name
- NCT00187109
- Testing
- Recombinant Human Thrombopoietin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- St. Jude Children's Research Hospital
Colorectal Neoplasms
Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy
The purpose of the study is to assessed the efficiency of treatment based on the objective response rate (RECIST 1.1)
- Trial name
- BEVIAC (NCT01677884)
- Testing
- Bevacizumab, Capecitabine, Irinotecan
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Colorectal Cancer
Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases
Bevacizumab, an anti-angiogenic agent, plus fluorouracil based chemotherapy is considered a new standard for the treatment of metastatic colorectal cancer.
- Trial name
- NCT00489697
- Testing
- real-time contrast-enhanced ultrasound imaging (CEUS)
- Where
- 12 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Tours
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, Lenvatinib
- Trial name
- NCT06632093
- Testing
- hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 84 people
- Sponsor
- First Hospital of China Medical University